Get to know us
EPTRI is a pan-European research infrastructure that connects specialised research units across Europe and beyond to strengthen and advance the paediatric research ecosystem.
Through integrated, end-to-end research services, EPTRI bridges the gap between scientific discovery and real-world application, accelerating the development of innovative health solutions for children.
VISION
To increase knowledge on children growth and ontogeny characteristics relevant for the identification of novel therapies dedicated to children and to provide services for their development
MISSION
To implement competences, research strategies, access to key technologies, standardised models, and analytical tools and to offer to public and private stakeholders qualified basic, preclinical and translational research services covering paediatric medicines discovery and development
OPEN CALL FOR THE DEVELOPMENT OF PAEDIATRIC AND ORPHAN MEDICAL DEVICES
OrphaDev4kids invites academics and individual researchers, startups and industrial players, organizations from diverse settings, and patient-led developers, to request for supporting services both for new device development and for the adaptation of existing products for the orphan and paediatric populations. More info here
PAEDIATRIC RESEARCH NEEDS SURVEY
This initiative is aimed at collecting insights from key stakeholders across the paediatric research and innovation ecosystem. We invite you to take a few minutes to complete the survey and share your perspectives and experience.
More information is available HERE.
Events
EPTRI General Assembly & Scientific Meeting
EPTRI is happy to announce its General Assembly and Scientific Meeting that will be held on 28 to 29 of July in Warsaw, Poland, at the premises of our member, Children’s Memorial Health Institute (CMHI)
Latest News
EMA has recommended granting a conditional marketing authorization to the first gene therapy to treat Haemophilia A
The European Medicines Agency (EMA) has recommended granting a conditional marketing authorisation in the European Union (EU) for Roctavian...
EMA has recommended granting marketing authorisation to the first three therapies for Rare Disorders in the European Union
The European Medicines Agency (EMA) recommended granting a marketing authorisation in the European Union (EU) for Xenpozyme (olipudase alfa),...
New EPTRI newsletter is out!
We are pleased to launch our March newsletter. In 2022 we will continue to advance paediatric research initiatives. We have several exciting news:...
Performances
EU and non-EU Countries
Members
© 2026 EPTRI. All rights reserved | Privacy policy | Terms and conditions | Cookie Law